无法接受或拒绝膀胱切除术的浸润性膀胱癌患者的管理。
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.
机构信息
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
出版信息
Ther Adv Urol. 2011 Jun;3(3):107-17. doi: 10.1177/1756287211407543.
Abstract
Bladder cancer is a common malignancy seen in older adults with coexisting medical illnesses. The management of patients with muscle invasive disease includes perioperative chemotherapy and radical cystectomy; however, patients may decline surgery and older patients with comorbid conditions may not be candidates for surgery and thus alternative treatment strategies are needed. Trimodality bladder preservation protocols for muscle invasive bladder cancer have generally included only those patients who are candidates for a salvage cystectomy. In this review, we discuss the current status of bladder preservation treatment options for patients with muscle-invasive disease who are not candidates for cystectomy or who decline surgery and highlight the need for clinical trials investigating novel treatment approaches in this older patient population.
摘要
膀胱癌是一种常见的恶性肿瘤，多见于患有并存疾病的老年人。肌层浸润性疾病患者的管理包括围手术期化疗和根治性膀胱切除术；然而，患者可能会拒绝手术，而且合并症较多的老年患者可能不适合手术，因此需要替代治疗策略。肌层浸润性膀胱癌的三联膀胱保留方案通常仅包括那些适合挽救性膀胱切除术的患者。在这篇综述中，我们讨论了对于不适合接受膀胱切除术或拒绝手术的肌层浸润性疾病患者的膀胱保留治疗选择的现状，并强调了在这一年龄段患者人群中进行新的治疗方法的临床试验的必要性。
相似文献
1
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.
Ther Adv Urol. 2011 Jun;3(3):107-17. doi: 10.1177/1756287211407543.
2
Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Urology. 2001 Sep;58(3):380-5. doi: 10.1016/s0090-4295(01)01219-5.
3
Bladder cancer.
Curr Treat Options Oncol. 2009 Aug;10(3-4):205-15. doi: 10.1007/s11864-009-0112-6.
4
Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
Cancer. 2003 Apr 15;97(8 Suppl):2115-9. doi: 10.1002/cncr.11282.
5
Organ preservation in muscle-invasive urothelial bladder cancer.
Curr Opin Oncol. 2024 May 1;36(3):155-163. doi: 10.1097/CCO.0000000000001038. Epub 2024 Mar 8.
6
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Bladder Cancer. 2016 Oct 27;2(4):405-413. doi: 10.3233/BLC-160072.
7
Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
BJU Int. 2011 May;107(10):1605-10. doi: 10.1111/j.1464-410X.2010.09564.x. Epub 2010 Sep 3.
8
Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
Am J Clin Oncol. 2019 Jan;42(1):36-41. doi: 10.1097/COC.0000000000000471.
9
Bladder sparing surgery in high-grade bladder cancer.
Exp Oncol. 2019 Jun;41(2):160-165. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-2.13207.
10
Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder.
Asian J Surg. 2014 Oct;37(4):184-9. doi: 10.1016/j.asjsur.2014.01.010. Epub 2014 Mar 14.
引用本文的文献
1
Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
Semin Radiat Oncol. 2023 Jul;33(3):262-278. doi: 10.1016/j.semradonc.2023.03.004.
2
Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience.
South Asian J Cancer. 2020 Jul;9(3):121-125. doi: 10.1055/s-0041-1723076. Epub 2021 Apr 26.
3
Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder.
Ir J Med Sci. 2020 May;189(2):431-438. doi: 10.1007/s11845-019-02074-9. Epub 2019 Aug 28.
4
Radical cystectomy in frail octogenarians in thoracic continuous spinal anesthesia and analgesia: a pilot study.
Ther Adv Urol. 2018 Sep 3;10(11):343-349. doi: 10.1177/1756287218795427. eCollection 2018 Nov.
5
Urothelial carcinoma management in elderly or unfit patients.
EJC Suppl. 2016 Mar;14(1):1-20. doi: 10.1016/j.ejcsup.2016.01.001. Epub 2016 Mar 22.
6
Transurethral resection and degeneration of bladder tumour.
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E812-6. doi: 10.5489/cuaj.363.
7
Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.
Biomed Res Int. 2013;2013:791406. doi: 10.1155/2013/791406. Epub 2013 Nov 28.
8
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E44-56. doi: 10.5489/cuaj.220.
9
Phase II study of everolimus in metastatic urothelial cancer.
BJU Int. 2013 Aug;112(4):462-70. doi: 10.1111/j.1464-410X.2012.11720.x. Epub 2013 Apr 3.
10
Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.
Curr Opin Oncol. 2012 May;24(3):278-83. doi: 10.1097/CCO.0b013e3283510587.
本文引用的文献
1
Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer.
Int J Oncol. 2011 Jan;38(1):13-24.
2
Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer.
J Urol. 2010 Aug;184(2):475-80. doi: 10.1016/j.juro.2010.04.008. Epub 2010 Jun 17.
3
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
J Urol. 2010 Jun;183(6):2171-7. doi: 10.1016/j.juro.2010.02.015.
4
Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13.
J Clin Oncol. 2010 Apr 20;28(12):2046-50. doi: 10.1200/JCO.2009.25.9978. Epub 2010 Mar 22.
5
Organ-sparing strategies in the management of invasive bladder cancer.
Expert Rev Anticancer Ther. 2009 Dec;9(12):1765-75. doi: 10.1586/era.09.151.
6
Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist.
Urology. 2009 Oct;74(4):858-64. doi: 10.1016/j.urology.2009.03.052. Epub 2009 Jul 22.
7
A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
Cancer. 2009 Oct 1;115(19):4547-53. doi: 10.1002/cncr.24490.
8
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
J Urol. 2009 Jun;181(6):2476-80; discussion 2480-1. doi: 10.1016/j.juro.2009.01.115. Epub 2009 Apr 16.
9
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18.
10
Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):511-7. doi: 10.1016/j.ijrobp.2008.08.021. Epub 2008 Oct 30.
Zotero 插件